NCT07382544

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Phase 1b Trial of Combined PRMT5 Inhibition With BMS-986504 and PARP Inhibition With Olaparib in Patients With Advanced Cancer With MTAP Loss

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.

Detailed description

Primary Objective: 1\. To determine the safety and tolerability of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss. Secondary Objectives: 1. To characterize the PK profile of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss. 2. To determine the preliminary antitumor activity of BMS-986504 in combination with olaparib with advanced solid tumors with MTAP loss. 3. To evaluate the pharmacodynamic activity of BMS-986504 in combination with olaparib in advanced solid tumors with MTAP loss. 4. To evaluate predictors of response and resistance to BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.

Conditions

• Advanced Cancer
• Solid Tumor

Interventions

Type	Name	Description
DRUG	MRTX1719	Given by mouth
DRUG	Olaparib	Given by mouth

Timeline

• Start date: 2026-02-12
• Primary completion: 2030-01-31
• Completion: 2032-01-31
• First posted: 2026-02-03
• Last updated: 2026-02-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study